Company announcement – No. 14 / 2019
Zealand Pharma announces amendments to its Articles of Association following the granting of warrants
Copenhagen, April 17, 2019 – Zealand Pharma (“Zealand”) announces that its Articles of Association have been amended to reflect the recent grant of warrants to the Company’s employees, as announced in Company Announcement no. 13/2019 on April 10, 2019.
The warrant program is an incentive scheme reflecting Zealand’s objective to attract and retain first-rate employees and help ensure shared short- and long-term interests for the management, employees and shareholders of the Company.
The amendments to Zealand’s Articles of Association entailed by the share capital increase have been registered today with the Danish Business Authority.
For further information, please contact:
Adam Steensberg, Interim Chief Executive Officer,
Executive Vice President and Chief Medical & Development Officer
Tel.: +45 50 60 36 01, e-mail: ast@zealandpharma.com
Lani Pollworth Morvan, Investor Relations and Communications
Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
